Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria
Ryan L Crass, Brandon Smith, Sven Adriaens, Sunny Chapel, Grant Langdon · 2024
Read Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria by Ryan L Crass, Brandon Smith, Sven Adriaens, Sunny Chapel, Grant Langdon (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11652457.txt.
Description
Crass, Smith, Adriaens, Chapel, and Langdon model how a newer drug for a rare blood disorder moves through patients' bodies and lifts their blood counts. The disorder destroys red cells, and older drugs leave some destruction unchecked. The newer drug, pegcetacoplan, blocks an earlier step of the immune cascade and addresses both destruction routes.
Pooling trial data from hundreds of patients, the team predicted drug levels and blood markers over time. Twice-weekly under-skin doses reached steady levels within weeks and held them with little swing. Heavier patients had somewhat higher exposure, but no trait changed results enough to matter clinically. The half-life ran about eight and a half days. The authors conclude the approved dose needs no per-group adjustment.
Catalog record
| CREATOR | Ryan L Crass, Brandon Smith, Sven Adriaens, Sunny Chapel, Grant Langdon |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |